Biomarin Pharmaceutical Inc. (BMRN)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin reports five-year Pompe disease data showing durable motor function
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
5 Undervalued Price-to-Book Stocks Worth Buying in August
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
